You are here: Industry Insights > CAR-T

News List

Growth-hungry Gilead acquires Kite at $12B for its nearly approved CAR-T treatment expressbpd
August 29, 2017
Gilead Sciences will buy Kite Pharma for nearly $12 billion, when Kite's cutting-edge CAR-T treatment is nearly approved.
Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing fiercepharma
August 22, 2017
Novartis CEO Joe Jimenez granted a cancer patient's request for a meeting at the company to discuss CAR-T pricing as its med tisagenlecleucel (CTL019) awaits an FDA decision date in October.
Small Biotechs will drive biggest development in decades on cancer treatments cphi-online
August 11, 2017
Small swift biotechs to lead a ‘golden age’ of next generation therapies such as CAR-T, combination therapies, innate immune system approaches, and newer check-point inhibitors.
Kite begins EU trial of CAR–T therapy pharmatimes
August 08, 2017
Kite Pharma has begun treating the first EU patients with its investigational CAR–T candidate, axicabtagene ciloleucel (axi-cel), in the safety expansion cohort of the ZUMA-1 trial.
Kite first to submit CAR-T therapy in Europe pharmatimes
August 02, 2017
Kite Pharma has submitted the first CAR-T cell therapy in Europe, seeking permission to market its axicabtagene ciloleucel (axi-cel) to treat patients with three subtypes of aggressive non-Hodgkin lymphoma
New 3-year data supports Kite ‘cure’ hopes for CAR-T pharmaphorum
July 24, 2017
A handful of patients with aggressive leukaemia appeared to have been cured thanks to CAR-T therapy, with some living more than four years with complete remission (CR).
Novartis CTL-019 unanimously passed by FDA: last mile for the marketing of the worlds’ first CAR-T en-cphi.cn
July 21, 2017
Novartis’ CAR-T therapy Tisagenlecleucel (CTL-019) evaluated by FDA is undoubtedly an important moment as there is only the final mile for the marketing of the world’s first CAR-T.
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory commi worldpharmanews
July 13, 2017
Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy.
Chinese “Legend” Talking about the Starry CAR-T Products on ASCO with Global CAR-T Giants en-cphi.cn
June 30, 2017
The ASCO (American Society of Clinical Oncology) Annual Meeting—an annual event on oncology, was successfully concluded in the beautiful McCormick Place, Chicago on June 6, 2017.
A Look at the Deaths That Plagued Juno (JUNO) and Kite Pharma (KITE)'s CAR-T Trials BioSpace.com
June 28, 2017
Although initially viewed as one of the most promising cancer therapies, CAR-T has had a number of setbacks, the most prominent being patient deaths.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page